• Explore /
  • Poster
  • / Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients.

Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients.

Abstract Poster

Authors

null

Deepa Bai Jagtap

Karmanos Cancer Institute, Wayne State University, Detroit, MI

Deepa Bai Jagtap , Archana Thakur , Abhinav Deol , Zaid Al-Kadhimi , Michael S. Simon , Lawrence E. Flaherty , Anthony Frank Shields , Dana Schalk , Elyse Paul , Vidya Kondadasula , Qin Liu , Lawrence G. Lum

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01022138

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3073)

DOI

10.1200/jco.2014.32.15_suppl.3073

Abstract #

3073

Poster Bd #

140

Abstract Disclosures

Similar Posters

First Author: Lawrence G. Lum

Poster

2014 ASCO Annual Meeting

Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.

Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.

First Author: Lawrence G. Lum

First Author: Dean F. Bajorin

First Author: Juan Martin-Liberal